AIMEDICS Succeeds with First UK Customers

Diabetes treatment developer AIMEDICS has announced the first use of the company’s HypoMon product in the UK involving 2 young people with type 1 diabetes who have successfully used it during August 2012.

AIMEDICS has developed a non-invasive sleep alarm system initially for people between 10 and 25 years of age with type I diabetes. Called HypoMon, the system identifies sleep time “hypos” – or dangerously low blood sugar levels – and alerts the patient and carer through a monitor and alarm.

Victor Skladnev, AIMEDICS CEO said: “We are very excited to have our first customers benefiting from the HypoMon in the UK. This is a critical step in AIMEDICS UK sales and marketing strategy to prove the value of the HypoMon to users and healthcare professionals.”

The HypoMon is more accurate, more comfortable and more affordable than anything on the diabetes treatment market. HypoMon assures a safer, more comfortable night’s sleep for all – both patients and carers.

The product has been rigorously trialed at children’s hospitals in Australia, and successfully identifies eight out of ten sleep time hypos.

AIMEDICS is one of 15 companies presenting at the Wholesale Investor Capital Showcase on September 17.
The event will held on September 17 in the PwC Offices, Darling Park Tower 2, Level 10, 201 Sussex Street, Sydney, from 12.30 to 4.30 pm.

To view the AIMEDICS opportunity on Wholesale Investor, click here.